Each year the World Health Organization (WHO) puts forward its recommendations for the composition of influenza virus for use in the Southern Hemisphere's influenza season. On the 23rd September 2022,the Australian Influenza Vaccine Committee (AIVC) confirmed their recommendation inline with the WHO recommendations.
In 2023 there will be Egg & Cell based quadrivalent vaccines available in Australia.
The Egg-based quadrivalent influenza vaccine components for the Australian 2023 influenza season will contain the following:
- an A/Sydney/5/2021 (H1N1)pdm09-like virus;
- an A/Darwin/9/2021 (H3N2)-like virus;
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.